A single-center RET retrospective study from South Korea analyzed 59 treated RET fusion-positive NSCLC patients, and the results showed that a total of 17 patients (28.8%) had a brain lesion at the initial diagnosis, while 11 additional patients (18.6%) developed brain metastases during follow-up (27). This evidence concerns the gene RET and non-small cell lung carcinoma.